title: Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke.
abstract: Forty-three patients with mild-moderate ischemic stroke were studied in the acute period and were divided into two groups. The experimental group consisted of 32 patients who were given Actovegin; the reference group consisted of 11 patients who were given piracetam. Patients were investigated before treatment and at 10 and 30 days; investigations included examination, points assessments of neurological disorders using the original Gusev-Skvortsova scale, neuropsychological tests using the MMSE scale, rheoencephalography, and electroencephalography. Analysis of changes in clinical features in patients treated with Actovegin during the acute period showed that Actovegin had clear positive effects both on general cerebral and on focal neurological symptoms. By the end of treatment, the extent of recovery of impaired functions, assessed in terms of total ischemic points and cognitive functions, was significantly greater in patients treated with Actovegin than in patients given piracetam. These data lead to the conclusion that Actovegin is effective in the treatment of patients with ischemic stroke.
authors.affiliation: Department of Neurology and Manual and Reflex Therapy, Urals State Medical Academy of Further Postgraduate Education, Russian Ministry of Health, Chelyabinsk, Russia.
authors.forename: E A
authors.initials: EA
authors.lastname: Derev'yannykh
authors.forename: G N
authors.initials: GN
authors.lastname: Bel'skaya
authors.forename: E A
authors.initials: EA
authors.lastname: Knoll
authors.forename: L G
authors.initials: LG
authors.lastname: Krylova
authors.forename: D V
authors.initials: DV
authors.lastname: Popov
mesh_terms: D000368:Aged; D002545:Brain Ischemia / Q000150:complications / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D004569:Electroencephalography; D005260:Female; D006418:Heme / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D020521:Stroke / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D014057:Tomography, X-Ray Computed
chemical_list: D000697:Central Nervous System Stimulants; D018697:Nootropic Agents; D006418:Heme; C015646:Actovegin; D010889:Piracetam